(NASDAQ: BBIO) Bridgebio Pharma's forecast annual revenue growth rate of 37.91% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.75%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10%.
Bridgebio Pharma's revenue in 2024 is $218,597,000.On average, 4 Wall Street analysts forecast BBIO's revenue for 2024 to be $41,382,138,815, with the lowest BBIO revenue forecast at $2,413,967,454, and the highest BBIO revenue forecast at $67,927,921,380. On average, 4 Wall Street analysts forecast BBIO's revenue for 2025 to be $57,834,543,354, with the lowest BBIO revenue forecast at $23,950,673,987, and the highest BBIO revenue forecast at $140,084,964,036.
In 2026, BBIO is forecast to generate $116,102,478,074 in revenue, with the lowest revenue forecast at $52,358,766,948 and the highest revenue forecast at $213,495,772,734.